Cargando…
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
BACKGROUND: The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown. METHODS: Retrospective analysis of consecutive patients with clear-cell mRCC who progressed on one of...
Autores principales: | Barata, Pedro Coelho, De Liano, Alfonso Gomez, Mendiratta, Prateek, Crolley, Valerie, Szabados, Bernadett, Morrison, Laura, Wood, Laura, Allman, Kimberly, Tyler, Allison, Martin, Allison, Gilligan, Timothy, Grivas, Petros, Ornstein, Moshe, Garcia, Jorge A., Powles, Thomas, Rini, Brian I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048048/ https://www.ncbi.nlm.nih.gov/pubmed/29795307 http://dx.doi.org/10.1038/s41416-018-0104-z |
Ejemplares similares
-
Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017) -
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
por: Zahoor, Haris, et al.
Publicado: (2018) -
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
por: Ornstein, Moshe C., et al.
Publicado: (2019) -
Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021) -
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)